ZA973809B - Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof. - Google Patents

Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof.

Info

Publication number
ZA973809B
ZA973809B ZA9703809A ZA973809A ZA973809B ZA 973809 B ZA973809 B ZA 973809B ZA 9703809 A ZA9703809 A ZA 9703809A ZA 973809 A ZA973809 A ZA 973809A ZA 973809 B ZA973809 B ZA 973809B
Authority
ZA
South Africa
Prior art keywords
polypeptide
gene sequence
membrane protein
outer membrane
moraxella catarrhalis
Prior art date
Application number
ZA9703809A
Other languages
English (en)
Inventor
Kenneth Tucker
Laura Plosila
Original Assignee
Antex Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Biolog Inc filed Critical Antex Biolog Inc
Publication of ZA973809B publication Critical patent/ZA973809B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA9703809A 1996-05-03 1997-05-02 Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof. ZA973809B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/642,712 US7341727B1 (en) 1996-05-03 1996-05-03 M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same

Publications (1)

Publication Number Publication Date
ZA973809B true ZA973809B (en) 1997-12-01

Family

ID=24577687

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9703809A ZA973809B (en) 1996-05-03 1997-05-02 Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof.

Country Status (25)

Country Link
US (6) US7341727B1 (cg-RX-API-DMAC7.html)
EP (1) EP0900025B1 (cg-RX-API-DMAC7.html)
JP (2) JP4401437B2 (cg-RX-API-DMAC7.html)
CN (2) CN100415871C (cg-RX-API-DMAC7.html)
AR (1) AR006999A1 (cg-RX-API-DMAC7.html)
AT (1) ATE244016T1 (cg-RX-API-DMAC7.html)
AU (1) AU723528B2 (cg-RX-API-DMAC7.html)
BG (1) BG64832B1 (cg-RX-API-DMAC7.html)
BR (1) BR9711090A (cg-RX-API-DMAC7.html)
CA (1) CA2253636C (cg-RX-API-DMAC7.html)
CZ (1) CZ298034B6 (cg-RX-API-DMAC7.html)
DE (1) DE69723254T2 (cg-RX-API-DMAC7.html)
EA (1) EA002743B1 (cg-RX-API-DMAC7.html)
EE (1) EE04684B1 (cg-RX-API-DMAC7.html)
ES (1) ES2202624T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20022695B (cg-RX-API-DMAC7.html)
HU (1) HU223004B1 (cg-RX-API-DMAC7.html)
NO (2) NO324816B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ332896A (cg-RX-API-DMAC7.html)
PL (3) PL189995B1 (cg-RX-API-DMAC7.html)
SK (1) SK284812B6 (cg-RX-API-DMAC7.html)
TW (1) TW541314B (cg-RX-API-DMAC7.html)
UA (1) UA68332C2 (cg-RX-API-DMAC7.html)
WO (1) WO1997041731A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA973809B (cg-RX-API-DMAC7.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
GB9714276D0 (en) 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
GB9808720D0 (en) * 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
EP1078065A2 (en) 1998-05-12 2001-02-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Compounds from moraxella catarrhalis
GB9810193D0 (en) * 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
GB9810285D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
US6673910B1 (en) 1999-04-08 2004-01-06 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics
ATE397666T1 (de) * 1999-05-24 2008-06-15 Glaxosmithkline Biolog Sa Neue verbindungen aus moraxella catarrhalis
GB9915031D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
GB9921691D0 (en) * 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
EP1214339B1 (en) * 1999-09-14 2007-08-01 GlaxoSmithKline Biologicals S.A. Polypeptides from moraxella (branhamella) catarrhalis
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
SE0102410D0 (sv) * 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
DE20321889U1 (de) 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
EP4005595A1 (en) 2005-04-08 2022-06-01 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
CN100357318C (zh) * 2005-10-11 2007-12-26 中山大学 美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ES2707499T3 (es) 2005-12-22 2019-04-03 Glaxosmithkline Biologicals Sa Vacuna de conjugado de polisacárido neumocócico
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
ZA200805602B (en) 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
CA2652957A1 (en) * 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
EA201391788A1 (ru) 2007-06-26 2014-08-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
CN103357014A (zh) 2007-07-12 2013-10-23 口腔健康澳洲私人有限公司 生物膜治疗
EP2176413A4 (en) 2007-07-12 2012-08-01 Oral Health Australia Pty Ltd IMMUNOLOGY TREATMENT FOR BIOFILMS
WO2009049013A2 (en) * 2007-10-09 2009-04-16 Tufts University Cholera vaccines
US8871213B2 (en) 2008-08-29 2014-10-28 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of P. gingivalis infection
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
ES2366735B1 (es) * 2009-10-08 2012-09-13 Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla Vacuna frente a acinetobacter baumannii.
US9700889B2 (en) 2009-11-23 2017-07-11 Cyvek, Inc. Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results
US9500645B2 (en) 2009-11-23 2016-11-22 Cyvek, Inc. Micro-tube particles for microfluidic assays and methods of manufacture
US9651568B2 (en) 2009-11-23 2017-05-16 Cyvek, Inc. Methods and systems for epi-fluorescent monitoring and scanning for microfluidic assays
WO2013134744A2 (en) 2012-03-08 2013-09-12 Cyvek, Inc Microfluidic assay assemblies and methods of manufacture
WO2011063408A1 (en) 2009-11-23 2011-05-26 Cyvek, Inc. Method and apparatus for performing assays
US9759718B2 (en) 2009-11-23 2017-09-12 Cyvek, Inc. PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use
US10065403B2 (en) 2009-11-23 2018-09-04 Cyvek, Inc. Microfluidic assay assemblies and methods of manufacture
US9855735B2 (en) 2009-11-23 2018-01-02 Cyvek, Inc. Portable microfluidic assay devices and methods of manufacture and use
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
US9567377B2 (en) 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa Immunogenic composition
US9169325B2 (en) 2010-04-13 2015-10-27 Celldex Therapeutics, Inc. Antibodies that bind human CD27 and uses thereof
US8501197B2 (en) 2010-04-30 2013-08-06 The Research Foundation for The State of New York Compositions and methods for stimulating immune response against Moraxella catarrhalis
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
CN103649759B (zh) 2011-03-22 2016-08-31 西维克公司 微流体装置以及制造方法和用途
RU2481401C2 (ru) * 2011-07-15 2013-05-10 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГОУ ВПО УГМА Минздравсоцразвития России) СПОСОБ ВЫЯВЛЕНИЯ β-ЛАКТАМАЗОПРОДУЦИРУЮЩИХ ОКСИДАЗОПОЗИТИВНЫХ ГРАМОТРИЦАТЕЛЬНЫХ ДИПЛОКОККОВ, ПОДОЗРИТЕЛЬНЫХ НА ПРИНАДЛЕЖНОСТЬ К MORAХELLA (BRANCHAMELLA) CATARRHALIS
US11210432B2 (en) * 2013-08-20 2021-12-28 Janus Technologies, Inc. Method and apparatus for selectively snooping and capturing data for secure computer interfaces
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10228367B2 (en) 2015-12-01 2019-03-12 ProteinSimple Segmented multi-use automated assay cartridge
US10865244B2 (en) 2016-04-18 2020-12-15 Celldex Therapeutics, Inc. Nucleic acids encoding agonistic antibodies that bind CD40
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
CN111157735B (zh) * 2018-11-07 2023-02-07 广州万孚生物技术股份有限公司 凝集性卡他莫拉菌单克隆抗体及其制备方法和应用
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN111778226B (zh) * 2020-07-21 2022-04-05 东北师范大学 一种水稻耐碱胁迫相关的质膜H+-ATPase蛋白及其应用
BR112023020303A2 (pt) 2021-04-09 2023-11-14 Celldex Therapeutics Inc Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675176A (en) * 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5552146A (en) * 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6335018B1 (en) 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
GB9809683D0 (en) * 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9812163D0 (en) * 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds

Also Published As

Publication number Publication date
GEP20022695B (en) 2002-05-27
WO1997041731A1 (en) 1997-11-13
EA199800973A1 (ru) 1999-06-24
US20020177200A1 (en) 2002-11-28
HUP9902695A3 (en) 2001-02-28
UA68332C2 (en) 2004-08-16
SK150998A3 (en) 1999-05-07
PL189374B1 (pl) 2005-07-29
US7341727B1 (en) 2008-03-11
CN1223549A (zh) 1999-07-21
CN100415871C (zh) 2008-09-03
AU3118097A (en) 1997-11-26
HU223004B1 (hu) 2004-03-01
EE9800373A (et) 1999-04-15
NZ332896A (en) 2000-05-26
PL330935A1 (en) 1999-06-07
PL189375B1 (pl) 2005-07-29
EA002743B1 (ru) 2002-08-29
NO324816B1 (no) 2007-12-10
JP2008161194A (ja) 2008-07-17
DE69723254D1 (de) 2003-08-07
US7914795B2 (en) 2011-03-29
NO985113D0 (no) 1998-11-02
EP0900025A4 (en) 2000-01-05
HK1021299A1 (en) 2000-06-09
US6214981B1 (en) 2001-04-10
CA2253636C (en) 2003-04-22
EP0900025B1 (en) 2003-07-02
SK284812B6 (sk) 2005-12-01
AU723528B2 (en) 2000-08-31
CZ298034B6 (cs) 2007-05-30
EP0900025A1 (en) 1999-03-10
PL189995B1 (pl) 2005-10-31
BG64832B1 (bg) 2006-06-30
JP2000510696A (ja) 2000-08-22
HK1095358A1 (zh) 2007-05-04
CN1222618C (zh) 2005-10-12
US7576179B2 (en) 2009-08-18
CZ352498A3 (cs) 1999-06-16
US20070087019A1 (en) 2007-04-19
NO20063711L (no) 1998-12-28
US20080145916A1 (en) 2008-06-19
US20100021492A1 (en) 2010-01-28
US7128910B2 (en) 2006-10-31
EE04684B1 (et) 2006-08-15
DE69723254T2 (de) 2004-04-22
AR006999A1 (es) 1999-10-13
BR9711090A (pt) 1999-08-17
ES2202624T3 (es) 2004-04-01
CA2253636A1 (en) 1997-11-13
BG102983A (en) 2000-05-31
NO985113L (no) 1998-12-28
TW541314B (en) 2003-07-11
ATE244016T1 (de) 2003-07-15
HUP9902695A2 (hu) 1999-12-28
JP4401437B2 (ja) 2010-01-20
CN1800359A (zh) 2006-07-12

Similar Documents

Publication Publication Date Title
ZA973809B (en) Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof.
AU7299796A (en) Cellulases, the genes encoding them and uses thereof
AU3274995A (en) Fibrin-binding peptides, dna coding therefor and uses thereof
ZA983148B (en) Modified TNFÓ, DNA encoding such modified TNFÓ and vacines comprising said TNFÓ and DNA.
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
ZA971272B (en) Gene expression.
AU6410099A (en) (moraxella catarrhalis) protein, nucleic acid sequence and uses thereof
EP0669396A4 (en) Novel polypeptides and DNA coding for them.
ZA974084B (en) Novel α-glucuronidases, production hereof and their uses.
AU4033199A (en) Polypeptides from moraxella (branhamella) catarrhalis
ZA972186B (en) Lytic peptides.
AU3670395A (en) Hippocampus-associated proteins, dna sequences coding therefor and uses thereof
ZA991443B (en) Leptospiral major outer membrane protein, LipL32.
ZA987660B (en) Novel tissue-specific calpains, their preparation and use.
HUP0103945A3 (en) Moraxella catarrhalis basb034 polypeptides and uses thereof
HK1016424A (en) Protein-106 polypeptide of the outer membrane of moraxella catarrhalis, gene sequence and uses thereof
HUP0102235A3 (en) Basbo27 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
AU6844596A (en) Nucleotide sequence encoding the cd33-like protein
ZA9711401B (en) Polypeptide of the bHLH family, corresponding nucleic acid sequence.
ZA9610510B (en) Novel peptides, the preparation and use thereof.
EP1018875A4 (en) MANUFACTURE OF INSECTICIDE PEPTIDES FROM THE SPIDER VENOM SEGESTRIA SP.
AU3502997A (en) Recombinant fusion protein comprising pdc-e2, bcoadc-e2, and ogdc-e2 and uses thereof
AU7519100A (en) Moraxella catarrhalis antigen, corresponding gene and uses thereof
ZA97195B (en) Wireless messaging system.
AU8953401A (en) A novel polypeptide, a human protein 16.83 ftsh and the polynucleotide encoding the polypeptide